Exact Mass: 503.169242
Exact Mass Matches: 503.169242
Found 316 metabolites which its exact mass value is equals to given mass value 503.169242
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
methyl (1S,2S,3R,5S,8R,9R,10R)-10-[(2R,3E,5E,7E)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-3,5,9-trimethyl-7-oxo-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylate
C26H33NO9 (503.21552080000004)
[(2S,3S,4S)-4,6-Diamino-3-hydroxy-1-[[(1S)-1-[(3S)-8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl]-3-methylbutyl]amino]-1,6-dioxohexan-2-yl] dihydrogen phosphate
C20H30N3O10P (503.16687300000007)
Gravacridonediol glucoside
C25H29NO10 (503.17913740000006)
Gravacridonediol glucoside is found in herbs and spices. Gravacridonediol glucoside is an alkaloid from Ruta graveolens (rue
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose is a constituent of blood group substance of human milk. Constituent of blood group substance of human milk
N-(4-Acetylphenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
C27H29N5O5 (503.21685840000004)
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists MRS-1706 is a potent and selective adenosine A2B receptor inverse agonist. MRS-1706 has Ki values of 1.39, 112, 157, and 230 nM for human A2B, A2A, A1 and A3 receptors respectively. MRS-1706 blocks adenosine-mediated cAMP induction[1][2].
Naloxone-3-glucuronide
C25H29NO10 (503.17913740000006)
(3aS)-5c-[(1R,2E,4E)-6-((E)-2,4-dioxo-pyrrolidin-3-ylidene)-6-hydroxy-1,3-dimethyl-hexa-2,4-dienyl]-2c,6t,9a-trimethyl-8-oxo-(9at)-octahydro-3ar,7c-epioxido-furo[3,2-b]oxocine-3c-carboxylic acid methyl ester|antibiotic Bu-2313-B|nocamycin-I
C26H33NO9 (503.21552080000004)
{(2R)-2-[alpha-D-glucopyranosyl(1->6)beta-D-glucopyranosyloxy]-2-(3-hydroxy-4-methoxyphenyl)}acetonitrile
C21H29NO13 (503.16388240000003)
Nocamycin I
C26H33NO9 (503.21552080000004)
An organic heterotricyclic compound and tetramic acid derivative originally isolated from an unidentified oligosporic actinomycete strain (no. E864-861) and found to be active against both Gram-positive and Gram-negative anaerobic bacteria as well as some aerobic bacteria such as Streptococci. The methyl ester of nocamycin E.
Ala His Asn Tyr
Ala His Tyr Asn
Ala Asn His Tyr
Ala Asn Asn Trp
Ala Asn Trp Asn
Ala Asn Tyr His
Ala Trp Asn Asn
Ala Tyr His Asn
Ala Tyr Asn His
Cys Glu Pro Arg
C19H33N7O7S (503.21620680000007)
Cys Glu Arg Pro
C19H33N7O7S (503.21620680000007)
Cys His Met Asn
Cys His Asn Met
Cys Met His Asn
Cys Met Asn His
Cys Asn His Met
Cys Asn Met His
Cys Pro Glu Arg
C19H33N7O7S (503.21620680000007)
Cys Pro Arg Glu
C19H33N7O7S (503.21620680000007)
Cys Arg Glu Pro
C19H33N7O7S (503.21620680000007)
Cys Arg Pro Glu
C19H33N7O7S (503.21620680000007)
Asp Asn Gln Gln
Asp Pro Ser Trp
Asp Pro Trp Ser
Asp Gln Asn Gln
Asp Gln Gln Asn
Asp Ser Pro Trp
Asp Ser Trp Pro
Asp Trp Pro Ser
Asp Trp Ser Pro
Glu Cys Pro Arg
C19H33N7O7S (503.21620680000007)
Glu Cys Arg Pro
C19H33N7O7S (503.21620680000007)
Glu Met Pro Gln
C20H33N5O8S (503.20497380000006)
Glu Met Gln Pro
C20H33N5O8S (503.20497380000006)
Glu Asn Asn Gln
Glu Asn Gln Asn
Glu Pro Cys Arg
C19H33N7O7S (503.21620680000007)
Glu Pro Met Gln
C20H33N5O8S (503.20497380000006)
Glu Pro Gln Met
C20H33N5O8S (503.20497380000006)
Glu Pro Arg Cys
C19H33N7O7S (503.21620680000007)
Glu Gln Met Pro
C20H33N5O8S (503.20497380000006)
Glu Gln Asn Asn
Glu Gln Pro Met
C20H33N5O8S (503.20497380000006)
Glu Arg Cys Pro
C19H33N7O7S (503.21620680000007)
Glu Arg Pro Cys
C19H33N7O7S (503.21620680000007)
Phe His Asn Ser
Phe His Ser Asn
Phe Asn His Ser
Phe Asn Ser His
Phe Ser His Asn
Phe Ser Asn His
Gly His Gln Tyr
Gly His Tyr Gln
Gly Asn Gln Trp
Gly Asn Trp Gln
Gly Gln His Tyr
Gly Gln Asn Trp
Gly Gln Trp Asn
Gly Gln Tyr His
Gly Trp Asn Gln
Gly Trp Gln Asn
Gly Tyr His Gln
Gly Tyr Gln His
His Ala Asn Tyr
His Ala Tyr Asn
His Cys Met Asn
His Cys Asn Met
His Phe Asn Ser
His Phe Ser Asn
His Gly Gln Tyr
His Gly Tyr Gln
His Met Cys Asn
His Met Asn Cys
His Asn Ala Tyr
His Asn Cys Met
His Asn Phe Ser
His Asn Met Cys
His Asn Ser Phe
His Asn Tyr Ala
His Gln Gly Tyr
His Gln Tyr Gly
His Ser Phe Asn
His Ser Asn Phe
His Tyr Ala Asn
His Tyr Gly Gln
His Tyr Asn Ala
His Tyr Gln Gly
Met Cys His Asn
Met Cys Asn His
Met Glu Pro Gln
C20H33N5O8S (503.20497380000006)
Met Glu Gln Pro
C20H33N5O8S (503.20497380000006)
Met His Cys Asn
Met His Asn Cys
Met Asn Cys His
Met Asn His Cys
Met Pro Glu Gln
C20H33N5O8S (503.20497380000006)
Met Pro Gln Glu
C20H33N5O8S (503.20497380000006)
Met Gln Glu Pro
C20H33N5O8S (503.20497380000006)
Met Gln Pro Glu
C20H33N5O8S (503.20497380000006)
Asn Ala His Tyr
Asn Ala Asn Trp
Asn Ala Trp Asn
Asn Ala Tyr His
Asn Cys His Met
Asn Cys Met His
Asn Asp Gln Gln
Asn Glu Asn Gln
Asn Glu Gln Asn
Asn Phe His Ser
Asn Phe Ser His
Asn Gly Gln Trp
Asn Gly Trp Gln
Asn His Ala Tyr
Asn His Cys Met
Asn His Phe Ser
Asn His Met Cys
Asn His Ser Phe
Asn His Tyr Ala
Asn Met Cys His
Asn Met His Cys
Asn Asn Ala Trp
Asn Asn Glu Gln
Asn Asn Gln Glu
Asn Asn Trp Ala
Asn Gln Asp Gln
Asn Gln Glu Asn
Asn Gln Gly Trp
Asn Gln Asn Glu
Asn Gln Gln Asp
Asn Gln Trp Gly
Asn Ser Phe His
Asn Ser His Phe
Asn Trp Ala Asn
Asn Trp Gly Gln
Asn Trp Asn Ala
Asn Trp Gln Gly
Asn Tyr Ala His
Asn Tyr His Ala
Pro Cys Glu Arg
C19H33N7O7S (503.21620680000007)
Pro Cys Arg Glu
C19H33N7O7S (503.21620680000007)
Pro Asp Ser Trp
Pro Asp Trp Ser
Pro Glu Cys Arg
C19H33N7O7S (503.21620680000007)
Pro Glu Met Gln
C20H33N5O8S (503.20497380000006)
Pro Glu Gln Met
C20H33N5O8S (503.20497380000006)
Pro Glu Arg Cys
C19H33N7O7S (503.21620680000007)
Pro Met Glu Gln
C20H33N5O8S (503.20497380000006)
Pro Met Gln Glu
C20H33N5O8S (503.20497380000006)
Pro Gln Glu Met
C20H33N5O8S (503.20497380000006)
Pro Gln Met Glu
C20H33N5O8S (503.20497380000006)
Pro Arg Cys Glu
C19H33N7O7S (503.21620680000007)
Pro Arg Glu Cys
C19H33N7O7S (503.21620680000007)
Pro Ser Asp Trp
Pro Ser Trp Asp
Pro Trp Asp Ser
Pro Trp Ser Asp
Gln Asp Asn Gln
Gln Asp Gln Asn
Gln Glu Met Pro
C20H33N5O8S (503.20497380000006)
Gln Glu Asn Asn
Gln Glu Pro Met
C20H33N5O8S (503.20497380000006)
Gln Gly His Tyr
Gln Gly Asn Trp
Gln Gly Trp Asn
Gln Gly Tyr His
Gln His Gly Tyr
Gln His Tyr Gly
Gln Met Glu Pro
C20H33N5O8S (503.20497380000006)
Gln Met Pro Glu
C20H33N5O8S (503.20497380000006)
Gln Asn Asp Gln
Gln Asn Glu Asn
Gln Asn Gly Trp
Gln Asn Asn Glu
Gln Asn Gln Asp
Gln Asn Trp Gly
Gln Pro Glu Met
C20H33N5O8S (503.20497380000006)
Gln Pro Met Glu
C20H33N5O8S (503.20497380000006)
Gln Gln Asp Asn
Gln Gln Asn Asp
Gln Trp Gly Asn
Gln Trp Asn Gly
Gln Tyr Gly His
Gln Tyr His Gly
Arg Cys Glu Pro
C19H33N7O7S (503.21620680000007)
Arg Cys Pro Glu
C19H33N7O7S (503.21620680000007)
Arg Glu Cys Pro
C19H33N7O7S (503.21620680000007)
Arg Glu Pro Cys
C19H33N7O7S (503.21620680000007)
Arg Pro Cys Glu
C19H33N7O7S (503.21620680000007)
Arg Pro Glu Cys
C19H33N7O7S (503.21620680000007)
Ser Asp Pro Trp
Ser Asp Trp Pro
Ser Phe His Asn
Ser Phe Asn His
Ser His Phe Asn
Ser His Asn Phe
Ser Asn Phe His
Ser Asn His Phe
Ser Pro Asp Trp
Ser Pro Trp Asp
Ser Trp Asp Pro
Ser Trp Pro Asp
Trp Ala Asn Asn
Trp Asp Pro Ser
Trp Asp Ser Pro
Trp Gly Asn Gln
Trp Gly Gln Asn
Trp Asn Ala Asn
Trp Asn Gly Gln
Trp Asn Asn Ala
Trp Asn Gln Gly
Trp Pro Asp Ser
Trp Pro Ser Asp
Trp Gln Gly Asn
Trp Gln Asn Gly
Trp Ser Asp Pro
Trp Ser Pro Asp
Tyr Ala His Asn
Tyr Ala Asn His
Tyr Gly His Gln
Tyr Gly Gln His
Tyr His Ala Asn
Tyr His Gly Gln
Tyr His Asn Ala
Tyr His Gln Gly
Tyr Asn Ala His
Tyr Asn His Ala
Tyr Gln Gly His
Tyr Gln His Gly
Gravacridonediol glucoside
C25H29NO10 (503.17913740000006)
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose
Rosuvastatin calcium
C22H27FN3NaO6S (503.1502214000001)
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM[2]. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].
4-methoxyphenyl 4,6-o-benzylidene-2-deoxy-2-phthalimido-beta-d-glucopyranoside
1-Decyl-3-Methylimidazolium Bis(Trifluoromethylsulfonyl)Imide
Trimebutine Maleate
C26H33NO9 (503.21552080000004)
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D005765 - Gastrointestinal Agents Trimebutine maleate is an orally anti-tumor agent. Trimebutine maleate selectively suppresses stemness and proliferation of ovarian cancer stem cells (CSCs). Trimebutine maleate reduces the colonic muscle hypercontractility, modulates gastrointestinal motility, induces apoptosis and can be used for the research of glioma/glioblastoma and irritable bowel syndrome[1][2][3][4][5][6].
5,5,5′,5′,5′′,5′′-Hexamethyltris(1,2,3-Dioxaphosphorinanemethan)-Amin 2,2′,2′′-Trioxid
((hydroxy((2-(6-pivalaMido-9H-purin-9-yl)ethoxy)Methyl)phosphoryl)oxy)Methyl pivalate
4-Methylphenyl 2-O-(phenylmethyl)-1-thio-beta-D-galactopyranoside triacetate
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide
C26H20F3N7O (503.16813460000003)
3-(1h-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid
C28H29N3O4S (503.1878674000001)
methyl (3R,5S,9R,10R)-10-[(2R,3E,5E,7Z)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-3,5,9-trimethyl-7-oxo-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylate
C26H33NO9 (503.21552080000004)
3-L-arginyl-AMP
An L-arginyl ester obtained by formal condensation of the carboxy group of L-arginine with the 3-hydroxy group of AMP.
(1R)-N-(3,5-dimethyl-4-isoxazolyl)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
C23H29N5O6S (503.18384540000005)
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
C28H29N3O6 (503.20562540000003)
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
C28H29N3O6 (503.20562540000003)
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
C28H29N3O6 (503.20562540000003)
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
C28H29N3O6 (503.20562540000003)
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
C28H29N3O6 (503.20562540000003)
2-[(2R,4aS,12aS)-8-(methanesulfonamido)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyphenyl)acetamide
C24H29N3O7S (503.17261240000005)
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
C25H33N3O6S (503.2089958000001)
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
C25H33N3O6S (503.2089958000001)
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
C28H29N3O6 (503.20562540000003)
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
C28H29N3O6 (503.20562540000003)
2-[(3S,6aR,8S,10aR)-1-(4-chlorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide
C22H34ClN3O6S (503.1856734000001)
[(1S)-2-[(3-chlorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C25H30ClN3O4S (503.1645450000001)
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
C25H33N3O6S (503.2089958000001)
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
C25H33N3O6S (503.2089958000001)
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
C28H29N3O6 (503.20562540000003)
2-[(3R,6aR,8S,10aR)-1-(4-chlorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide
C22H34ClN3O6S (503.1856734000001)
[(1R)-2-[(3-chlorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C25H30ClN3O4S (503.1645450000001)
(1S)-N-(3,5-dimethyl-4-isoxazolyl)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
C23H29N5O6S (503.18384540000005)
4-[7-[Ethyl(5-carboxypentyl)amino]-2-oxo-2H-1-benzopyran-3-yl]-1-(3-sulfonatopropyl)pyridinium
YH239-EE
C25H27Cl2N3O4 (503.13785220000005)
YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent. IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction. YH239-EE induces cell cycle arrest and causes potent cell apoptosis via activation of p53 and downstream targets in four AML cells (OCI-AML-3 and MOLM-13 with wt p53, NB4 with p53 mutation, and HL60 with p53 deletion).
4-amino-3-hydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-2-(phosphonooxy)hexanediimidic acid
C20H30N3O10P (503.16687300000007)
(2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl)oxysulfonic acid
(2r)-2-(3-hydroxy-4-methoxyphenyl)-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}acetonitrile
C21H29NO13 (503.16388240000003)
(2s)-5-hydroxy-1-[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3-dihydroindole-2-carboxylic acid
C24H25NO11 (503.14275399999997)
(1r,4r,8s,10r,12r,13s,16s,17r)-17,19-dihydroxy-13-(methoxymethyl)-8,12-dimethyl-2,7,15-trioxo-14-oxa-18-azapentacyclo[10.7.0.0¹,¹⁶.0³,¹¹.0⁴,⁸]nonadeca-3(11),18-dien-10-yl 2-methylbutanoate
C26H33NO9 (503.21552080000004)
(1'r,2r,9r,9as,12'r)-2-benzyl-15'-hydroxy-12'-methyl-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione
(1r,4r,8s,10r,12r,13s,16s,17s)-17,19-dihydroxy-13-(methoxymethyl)-8,12-dimethyl-2,7,15-trioxo-14-oxa-18-azapentacyclo[10.7.0.0¹,¹⁶.0³,¹¹.0⁴,⁸]nonadeca-3(11),18-dien-10-yl 2-methylbutanoate
C26H33NO9 (503.21552080000004)
7-(2-{2-[4-(3-isopropyloxiran-2-yl)but-3-en-2-yl]-1,3-thiazol-4-yl}-1,3-thiazol-4-yl)-3,5-dimethoxy-4-methylhepta-2,6-dienimidic acid
C25H33N3O4S2 (503.19123780000007)
(2e,4r,5s,6e)-7-(2-{2-[(2s,3e)-4-(3-isopropyloxiran-2-yl)but-3-en-2-yl]-1,3-thiazol-4-yl}-1,3-thiazol-4-yl)-3,5-dimethoxy-4-methylhepta-2,6-dienimidic acid
C25H33N3O4S2 (503.19123780000007)
ethyl 4-[(1-{10-acetyl-7-ethoxy-3,11,13-trihydroxy-2,12-dimethyl-5-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(13),3,9,11-tetraen-4-yl}ethylidene)amino]butanoate
C26H33NO9 (503.21552080000004)
[(1e)-2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl]oxysulfonic acid
methyl 2-{7-[(3e,5e)-7-(2-hydroxy-4-oxo-1,5-dihydropyrrol-3-yl)-4-methyl-7-oxohepta-3,5-dien-2-yl]-1,6-dimethyl-4-oxo-8,9-dioxaspiro[bicyclo[3.3.1]nonane-2,2'-oxiran]-3'-yl}propanoate
C26H33NO9 (503.21552080000004)
methyl 2-{7-[(3e,5e)-7-hydroxy-7-(2-hydroxy-4-oxo-5h-pyrrol-3-ylidene)-4-methylhepta-3,5-dien-2-yl]-1,6-dimethyl-4-oxo-8,9-dioxaspiro[bicyclo[3.3.1]nonane-2,2'-oxiran]-3'-yl}propanoate
C26H33NO9 (503.21552080000004)
2-[(7s)-7-(acetyloxy)-5-chloro-3-[(5s)-3,5-dimethylhepta-1,3-dien-1-yl]-7-methyl-6,8-dioxoisoquinolin-2-yl]-4-methylpentanoic acid
C27H34ClNO6 (503.2074534000001)
[(1z)-2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl]oxysulfonic acid
ethyl 4-({1-[(2s,7r)-10-acetyl-7-ethoxy-3,11,13-trihydroxy-2,12-dimethyl-5-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(13),3,9,11-tetraen-4-yl]ethylidene}amino)butanoate
C26H33NO9 (503.21552080000004)
2-(3-hydroxy-4-methoxyphenyl)-2-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}acetonitrile
C21H29NO13 (503.16388240000003)
17,19-dihydroxy-13-(methoxymethyl)-8,12-dimethyl-2,7,15-trioxo-14-oxa-18-azapentacyclo[10.7.0.0¹,¹⁶.0³,¹¹.0⁴,⁸]nonadeca-3(11),18-dien-10-yl 2-methylbutanoate
C26H33NO9 (503.21552080000004)
2-benzyl-15'-hydroxy-12'-methyl-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione
5-hydroxy-1-[3-(4-hydroxyphenyl)prop-2-enoyl]-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3-dihydroindole-2-carboxylic acid
C24H25NO11 (503.14275399999997)
(2e,4r,5s,6e)-7-(2-{2-[(2s,3e)-4-[(2s,3r)-3-isopropyloxiran-2-yl]but-3-en-2-yl]-1,3-thiazol-4-yl}-1,3-thiazol-4-yl)-3,5-dimethoxy-4-methylhepta-2,6-dienimidic acid
C25H33N3O4S2 (503.19123780000007)